CAR T-Cell Therapy Shows Promise in Relapsed/Refractory Myeloma – OncLive
OncLive |
CAR T-Cell Therapy Shows Promise in Relapsed/Refractory Myeloma
OncLive Berdeja: bb2121 is a CAR-T product directed at BCMA that uses a 4-1BB costimulatory domain and it is for patients with relapsed/refractory multiple myeloma. We presented the completed phase I dose-escalation portion of the trial. We have started the … |
